7Aisner J,Musanti R,Beers S,et al.Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase Ⅰ and Ⅱ resistance:a pharmacodynamically based phase Ⅰ trial[J].Clin Cancer Res,2003,9(7):2504-2509.
9Guichard S,Arnould S,Hennebelle I,et al.Combination of oxaliplatin and irinotecan on human colon cancer cell lines:activity in vitro and in vivo[J].Anticancer Drugs,2001,12(9):741-751.
8[5]Matsuoka H, Yano K, Takiguchi S, et al. Advantage of combined treatment of CPT-11 and 5-fluorouracil. Anticancer Res,1995,15(4):1447-1452.
9[6]Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol,1992,10(11):1775-1780.
1Chou TC, Motzer R J, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design [ J ]. J Natl Cancer Inst, 1994,86 (20) : 1517 - 1524.
2Chou TC, Talalay P. Quantitative analysis of dose - effect relationships: the combined effects of muhiple drugs or enzyme inhibitors [J]. Adv Enzyme Regul, 1984,22:27 -55.
35 Fukuda M, Nishio K, Kanzawa F, et al. Synergism between cisplatin and topoisomerase I inhibitors, NB - 506 and SN - 38, in human small cell lung cancer ceils [ J ]. Cancer Res, 1996,56 (4) :789 -793.
4Goldwasser F, Bozec L, Zeghari - Squalli N, et al. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV - 1 human ovarian cancer cell line[J]. Anticancer Drugs, 1999,10(2) :195 -201.
5Zeghari - Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase Ⅰ inhibitor SN -38 and the diaminocyclohexane platinum derivative oxaliplatin[J]. Clin Cancer Res, 1999,5(5) :1189 - 1196.
6Guichard S, Amould S, Hennebelle I, et al. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo [J]. Anticancer Drugs, 2001,12 (9) :741 - 751.
7Kanzawa F, Koizumi F, Koh Y, et al. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase Ⅰ inhibitor irinotecan and the mechanism of this interaction[J]. Clin Cancer Res, 2001,7( 1 ) :202 -209.
8Goldwasser F, Shimizu T, Jackman J, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells [ J ]. Cancer Res, 1996,56 ( 19 ) : 4430 - 4437.
9Amould S, Guichard S, Hennebelle I, et al. Contribution of apoptosis in the cytotoxicity of the oxaliplatin - irinotecan combination in the HT29 human colon adenocarcinoma cell line[J]. Biochem Pharmacol, 2002,64(8 ) : 1215 - 1226.
